PL2634185T3 - Inhibitory kinazy TYK2 - Google Patents

Inhibitory kinazy TYK2

Info

Publication number
PL2634185T3
PL2634185T3 PL13157419T PL13157419T PL2634185T3 PL 2634185 T3 PL2634185 T3 PL 2634185T3 PL 13157419 T PL13157419 T PL 13157419T PL 13157419 T PL13157419 T PL 13157419T PL 2634185 T3 PL2634185 T3 PL 2634185T3
Authority
PL
Poland
Prior art keywords
kinase inhibitors
tyk2 kinase
tyk2
inhibitors
kinase
Prior art date
Application number
PL13157419T
Other languages
English (en)
Inventor
John Charles Reader
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of PL2634185T3 publication Critical patent/PL2634185T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL13157419T 2012-03-02 2013-03-01 Inhibitory kinazy TYK2 PL2634185T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261605952P 2012-03-02 2012-03-02
EP13157419.6A EP2634185B1 (en) 2012-03-02 2013-03-01 TYK2 kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2634185T3 true PL2634185T3 (pl) 2016-06-30

Family

ID=47754367

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13157419T PL2634185T3 (pl) 2012-03-02 2013-03-01 Inhibitory kinazy TYK2

Country Status (5)

Country Link
US (3) US20130231340A1 (pl)
EP (2) EP2634185B1 (pl)
DK (2) DK2634185T3 (pl)
ES (1) ES2566205T3 (pl)
PL (1) PL2634185T3 (pl)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201202027D0 (en) 2012-02-06 2012-03-21 Sareum Ltd Pharmaceutical compounds
DK2634185T3 (en) 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
CN105793245B (zh) * 2013-09-03 2018-03-20 萨勒姆有限公司 药物化合物
GB201617871D0 (en) * 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds
EP3551034A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
CN110072519A (zh) 2016-12-14 2019-07-30 普罗根尼蒂公司 使用jak抑制剂治疗胃肠道疾病及装置
TWI868528B (zh) 2017-03-08 2025-01-01 日商武田藥品工業股份有限公司 Tyk2抑制劑之生產方法
MX2020010815A (es) 2018-04-13 2020-12-11 Incyte Corp Biomarcadores para enfermedad de injerto contra hospedero.
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
GB201816369D0 (en) * 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds
EP4041204A1 (en) 2019-10-10 2022-08-17 Incyte Corporation Biomarkers for graft-versus-host disease
US12360120B2 (en) 2019-10-10 2025-07-15 Incyte Corporation Biomarkers for graft-versus-host disease
US20230107927A1 (en) 2020-02-28 2023-04-06 First Wave Bio, Inc. Methods of treating iatrogenic autoimmune colitis
GB202005114D0 (en) 2020-04-07 2020-05-20 Sareum Ltd Crystalline Forms of a Pharmaceutical Compound
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
EP4423086A1 (en) 2021-10-25 2024-09-04 Kymera Therapeutics, Inc. Tyk2 degraders and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
GB1497536A (en) 1973-12-17 1978-01-12 Lilly Industries Ltd 2-acylaminooxazoles methods for their preparation and their use
JPS56159794A (en) 1980-05-12 1981-12-09 Tokyo Optical Length or angle measuring device
JPH0753716B2 (ja) 1986-07-02 1995-06-07 吉富製薬株式会社 イミダゾ−ルカルボキサミド誘導体
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
NZ522696A (en) 2000-06-28 2004-08-27 Astrazeneca Ab Substituted quinazoline derivatives and their use as inhibitors
MXPA03003868A (es) 2000-10-30 2003-07-28 Janssen Pharmaceutica Nv Inhibidores de tripeptidil peptidasa.
EP1554269A1 (en) 2002-07-09 2005-07-20 Vertex Pharmaceuticals Incorporated Imidazoles, oxazoles and thiazoles with protein kinase inhibiting activities
PL1684750T3 (pl) 2003-10-23 2010-10-29 Ab Science 2-Aminoarylooksazole jako inhibitory kinazy tyrozynowej
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
EP1932833B1 (en) 2005-10-07 2012-08-01 Kissei Pharmaceutical Co., Ltd. Nitrogenated heterocyclic compound and pharmaceutical composition comprising the same
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
ATE480525T1 (de) 2006-05-12 2010-09-15 Ab Science Neues verfahren zur synthese von 2- aminooxazolverbindungen
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
EP2166846B1 (en) 2007-06-20 2012-10-17 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2278969B1 (en) 2008-04-21 2013-02-13 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
EP2299816B1 (en) 2008-06-18 2013-11-13 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
CA2730010A1 (en) 2008-07-09 2010-01-14 Merck Sharp & Dohme Corp. Inhibitors of janus kinases
EP2166006A1 (en) 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
JP2013522267A (ja) 2010-03-17 2013-06-13 エフ.ホフマン−ラ ロシュ アーゲー イミダゾピリジン化合物、組成物、および使用法
EP2588105A1 (en) 2010-07-01 2013-05-08 Cellzome Limited Triazolopyridines as tyk2 inhibitors
WO2012021611A1 (en) * 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
WO2013055645A1 (en) 2011-10-12 2013-04-18 Array Biopharma Inc. 5,7-substituted-imidazo[1,2-c]pyrimidines
DK2634185T3 (en) 2012-03-02 2016-03-21 Sareum Ltd Tyk2 kinase inhibitors
GB201617871D0 (en) * 2016-10-21 2016-12-07 Sareum Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
DK3040336T3 (da) 2020-06-22
EP3040336A1 (en) 2016-07-06
EP2634185A1 (en) 2013-09-04
ES2566205T3 (es) 2016-04-11
DK2634185T3 (en) 2016-03-21
US20130231340A1 (en) 2013-09-05
US20210087154A1 (en) 2021-03-25
US20190210983A1 (en) 2019-07-11
US10882829B2 (en) 2021-01-05
US11673870B2 (en) 2023-06-13
EP3040336B1 (en) 2020-04-08
EP2634185B1 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
IL261282A (en) Furinone compounds as kinase inhibitors
ZA201501009B (en) Imidazotriazinecarbonitriles useful as kinase inhibitors
ZA201508847B (en) Serine/threonine kinase inhibitors
PL2710007T3 (pl) Inhibitory kinazy
ZA201404156B (en) Kinase inhibitors
EP2831080A4 (en) LACTAMES INHIBITORS OF KINASES
LT2903618T (lt) Rho kinazės inhibitoriai
IL229028A0 (en) Kinase inhibitors
EP2900668A4 (en) INHIBITORS OF MULTIPLE KINASE PATHWAYS
IL228103A0 (en) Amino-quinolines as kinase inhibitors
EP2782580A4 (en) SELECTIVE INHIBITORS OF KINASES
SG11201500973WA (en) Amino-quinolines as kinase inhibitors
ZA201409256B (en) 1,2,4-triazine-6-carboxamide kinase inhibitors
EP2870158A4 (en) PROTEIN KINASE INHIBITORS
IL232701A0 (en) Pyrazine kinase inhibitors
ZA201404157B (en) Kinase inhibitors
EP2855484A4 (en) PROTEIN KINASE INHIBITORS
EP2900243A4 (en) BICYCLIC OXA LACTAM KINASE HEMMER